ANNX — Annexin Pharmaceuticals AB (publ) Balance Sheet
0.000.00%
Last trade - 00:00- SEK98.12m
- SEK70.73m
Annual balance sheet for Annexin Pharmaceuticals AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 49.5 | 31.1 | 21.4 | 16.3 | 27.4 |
| Net Total Receivables | 1.01 | 1.86 | 2.63 | 0.418 | 0.376 |
| Prepaid Expenses | |||||
| Total Current Assets | 50.7 | 33.6 | 24.9 | 17.4 | 28.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.35 | 1.26 | 1.17 | 1.08 | 1.12 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 52.8 | 36.7 | 26.8 | 19 | 30.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.06 | 6.53 | 7.95 | 5.32 | 5.22 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 6.06 | 6.53 | 7.95 | 5.32 | 5.22 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 46.7 | 30.2 | 18.8 | 13.7 | 24.9 |
| Total Liabilities & Shareholders' Equity | 52.8 | 36.7 | 26.8 | 19 | 30.2 |
| Total Common Shares Outstanding |